Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478553 · ClinicalTrials.gov registry record
The Genetics of Pulmonary Fibrosis
A clinical trial of Idiopathic Pulmonary Fibrosis (IPF), sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03478553 is a study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 1,000 participants, above the 372-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (169% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03478553, a study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Conditions Studied
Interventions
- OTHER Blood draw
- OTHER Questionnaire
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03478553
The ClinicalTrials.gov registry entry for NCT03478553 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 372-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (169% higher). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 2 interventions - of which Blood draw is the first listed.
NCT03478553 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03478553 about?
NCT03478553 is a clinical study titled "The Genetics of Pulmonary Fibrosis". This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
What is the current status of trial NCT03478553?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2018-01-18. Estimated completion is 2026-12-31.
What conditions does trial NCT03478553 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).
What interventions are being tested in trial NCT03478553?
The interventions under investigation include: Blood draw (OTHER), Questionnaire (OTHER).
Who is sponsoring clinical trial NCT03478553?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478553 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis (IPF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
RECRUITING · Phase 2
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.